Dr Munazza Afzal, MD | |
514 Gramatan Ave, Suite P3, Mount Vernon, NY 10552-3054 | |
(914) 699-7427 | |
(914) 699-7428 |
Full Name | Dr Munazza Afzal |
---|---|
Gender | Female |
Speciality | Rheumatology |
Experience | 34 Years |
Location | 514 Gramatan Ave, Mount Vernon, New York |
Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447219795 | NPI | - | NPPES |
02188136 | Medicaid | NY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RR0500X | Internal Medicine - Rheumatology | 218978 (New York) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
New York-presbyterian Hospital | New york, NY | Hospital |
Montefiore Mount Vernon Hospital | Mount vernon, NY | Hospital |
Entity Name | Munazza Afzal Md Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1255481214 PECOS PAC ID: 1658351580 Enrollment ID: O20040722000044 |
News Archive
Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free - at least in mice - of dangerous side effects plaguing some current diabetes medications.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.
A team of scientists at the University of Oklahoma Health Sciences Center has created the first genetic research model for a microscopic part of the eye that when missing causes blindness. The research appears in a recent issue of the Journal of Biological Chemistry.
Redspin, Inc., a leading provider of HIPAA security risk assessments and penetration testing services, today released an IT security advisory specifically for senior executives in the healthcare industry.
A recent review of the scientific literature concluded that low-calorie (or no-calorie) sweeteners may be of help in resolving the obesity problem.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Munazza Afzal, MD 514 Gramatan Ave, Suite P3, Mount Vernon, NY 10552-3054 Ph: (914) 699-7427 | Dr Munazza Afzal, MD 514 Gramatan Ave, Suite P3, Mount Vernon, NY 10552-3054 Ph: (914) 699-7427 |
News Archive
Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free - at least in mice - of dangerous side effects plaguing some current diabetes medications.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.
A team of scientists at the University of Oklahoma Health Sciences Center has created the first genetic research model for a microscopic part of the eye that when missing causes blindness. The research appears in a recent issue of the Journal of Biological Chemistry.
Redspin, Inc., a leading provider of HIPAA security risk assessments and penetration testing services, today released an IT security advisory specifically for senior executives in the healthcare industry.
A recent review of the scientific literature concluded that low-calorie (or no-calorie) sweeteners may be of help in resolving the obesity problem.
› Verified 3 days ago
Ms. Deepthi Sara Sony, MD Rheumatology Medicare: May Accept Medicare Assignments Practice Location: 107 W 4th St, Administration, Mount Vernon, NY 10550 Phone: 914-699-7200 Fax: 914-699-0837 | |
Asim Shahid, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 105 Stevens Ave Ste 306, Mount Vernon, NY 10550 Phone: 914-863-0056 | |
Dariush Alaie, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 12 N 7th Ave, Mount Vernon, NY 10550 Phone: 914-664-8000 | |
Susan M Santry, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 127e Lincoln Ave, Mount Vernon, NY 10552 Phone: 203-249-6767 Fax: 203-531-1901 | |
Dr. Muhammad Irfan Qadir, M.D. Rheumatology Medicare: May Accept Medicare Assignments Practice Location: 514 Gramatan Ave, Suite P3, Mount Vernon, NY 10552 Phone: 845-627-6114 Fax: 845-627-8404 | |
Dr. Shamima Chowdhury, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 107 West 4th Street, Mount Vernon Neighborhood Health Center, Mount Vernon, NY 10550 Phone: 914-699-7200 Fax: 914-699-0837 | |
Dr. Leslie Dawn Julien, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 12 N 7th Ave, Mount Vernon, NY 10550 Phone: 914-664-8000 Fax: 914-664-8015 |